Travere Therapeutics (TVTX) Non Operating Income (2013 - 2026)
Travere Therapeutics (TVTX) posted Non Operating Income of $193000.0 for Q1 2026, down 98.3% on a QoQ basis from $11.4 million in Q4 2025, and down 87.02% year-over-year from $1.5 million in Q1 2025.
Travere Therapeutics (TVTX) Non Operating Income (2013 - 2026) Analysis & Trends
Travere Therapeutics' Non Operating Income history runs 14 years deep, the most recent figure standing at $193000.0 for Q1 2026.
- Quarterly Non Operating Income fell 87.02% year-over-year to $193000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (up 818.59% YoY) and the FY2025 annual result came in at $13.6 million, up 308.53% from the prior year.
- Non Operating Income was $193000.0 for Q1 2026 at Travere Therapeutics, down from $11.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $11.4 million in Q4 2025 and bottomed at -$9.8 million in Q1 2022.
- A 5-year average of $949411.8 and a median of $883000.0 in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income sank 189.4% — and 2025, when it surged 2762.22%.
- Travere Therapeutics' Non Operating Income stood at $1.1 million in 2022, then soared by 405.31% to $5.7 million in 2023, then tumbled by 93.04% to $397000.0 in 2024, then jumped by 2762.22% to $11.4 million in 2025, then tumbled by 98.3% to $193000.0 in 2026.
- Business Quant data shows TVTX's Non Operating Income at $193000.0 in Q1 2026, $11.4 million in Q4 2025, and $783000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | 193,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 193,000.00 |
| Dec 31, 2025 | 11.36 Mn |
| Sep 30, 2025 | 783,000.00 |
| Jun 30, 2025 | -85,000.00 |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 397,000.00 |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | -1.86 Mn |
| Mar 31, 2024 | 3.47 Mn |
| Dec 31, 2023 | 5.71 Mn |
| Sep 30, 2023 | 3.36 Mn |
| Jun 30, 2023 | 2.08 Mn |
| Mar 31, 2023 | 883,000.00 |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | -1.31 Mn |
| Jun 30, 2022 | -2.97 Mn |
| Mar 31, 2022 | -9.79 Mn |
| Dec 31, 2021 | -6.14 Mn |
| Sep 30, 2021 | -4.90 Mn |
| Jun 30, 2021 | -3.65 Mn |